<DOC>
	<DOCNO>NCT00003577</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether combination chemotherapy plus epirubicin effective combination chemotherapy alone stage I stage II breast cancer . PURPOSE : This randomized phase III trial study combination chemotherapy alone see well work compare combination chemotherapy epirubicin treat woman stage I stage II breast cancer undergone surgery remove tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Epirubicin Treating Women With Stage I Stage II Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free overall survival woman early stage breast cancer treat adjuvant cyclophosphamide , methotrexate , fluorouracil without epirubicin . - Compare quality life subgroup patient treat regimen . OUTLINE : This randomize study . Patients stratify accord radiotherapy timing ( concurrent versus sequential ) , nodal status ( negative versus 1-3 versus least 4 ) , age ( 50 versus 50 ) , grade , tumor size . Patients randomize one two treatment arm . - Arm I : Patients receive oral cyclophosphamide day 1-14 methotrexate IV fluorouracil IV day 1 8 . Treatment repeat every 4 week 6 course . - Arm II : Patients receive epirubicin IV day 1 every 3 week 4 course follow cyclophosphamide , methotrexate , fluorouracil , arm I , 4 course . Some patient may receive radiotherapy chemotherapy . Treatment continue absence disease progression unacceptable toxicity . Quality life assess subset patient ( N=500 ) chemotherapy start , 3 month treatment , end chemotherapy , 6 , 12 , 18 month treatment . Patients follow annually 10 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 2,000 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histological confirmation invasive , early stage breast cancer Prior complete excision tumor require ( wide local excision mastectomy ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Pre , peri , postmenopausal Performance status : Not specify Hematopoietic : Adequate bone marrow function Hepatic : Adequate hepatic function Renal : Adequate renal function Other : No prior cancer except basal cell carcinoma carcinoma situ Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Concurrent hormone therapy allow Radiotherapy : No prior radiotherapy Concurrent radiotherapy allow Surgery : See Disease Characteristics No 6 week since prior surgery breast</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>